Expected Moves

Da Ren Tang is projected to announce Q3 2026 earnings, where the market will scrutinize revenue stabilization after a severe year-over-year contraction. From the $35.35 anchor, an upside surprise could rally shares to $38.00, while continued margin deterioration targets the $33.50 floor.

Expected monthly status update on the bankruptcy liquidation of the 55%-owned Tianjin Shin Poong Pharmaceutical subsidiary. Assuming a $33.50 base, successful limitation of liabilities opens a path to $35.20, whereas unexpected write-downs pressure the stock to $32.00.

Market updates on the 180M CNY Tianjin Modern TCM Innovation Project, focused on integrating AI into production traceability. From a $32.00 entry, positive adoption metrics aim for $35.50, while delays drop the valuation to $30.50.

Full-year 2026 financials and 2027 forward guidance will be released, assessing the impact of domestic healthcare policies and global trade dynamics under President Trump. Anchored at $35.50, a return to top-line growth could propel the stock to $39.00, while a prolonged slump forces a retreat to $33.50.

The Board typically approves the annual equity distribution in late June. Progressing from $39.00, a robust payout affirms cash flow strength targeting $42.00, whereas a dividend cut drops shares to $36.50.